Richard Chesworth's most recent trade in Kymera Therapeutics Inc was a trade of 33,779 Common Stock done at an average price of $60.1 . Disclosure was reported to the exchange on Aug. 27, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics Inc | Richard Chesworth | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 60.12 per share. | 27 Aug 2021 | 33,779 | 0 | - | 60.1 | 2,030,864 | Common Stock |
| Kymera Therapeutics Inc | Richard Chesworth | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2021 | 33,779 | 263,340 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Richard Chesworth | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.00 per share. | 27 Aug 2021 | 33,779 | 33,779 | - | 20 | 675,580 | Common Stock |
| Kymera Therapeutics Inc | Richard Chesworth | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.00 per share. | 17 Aug 2021 | 54,000 | 54,000 | - | 20 | 1,080,000 | Common Stock |
| Kymera Therapeutics Inc | Richard Chesworth | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 54,000 | 297,119 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Richard Chesworth | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 50.37 per share. | 17 Aug 2021 | 41,975 | 3,216 | - | 50.4 | 2,114,243 | Common Stock |
| Kymera Therapeutics Inc | Richard Chesworth | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 49.90 per share. | 17 Aug 2021 | 8,809 | 45,191 | - | 49.9 | 439,612 | Common Stock |
| Kymera Therapeutics Inc | Richard Chesworth | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 51.68 per share. | 17 Aug 2021 | 2,928 | 288 | - | 51.7 | 151,325 | Common Stock |
| Kymera Therapeutics Inc | Richard Chesworth | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 52.09 per share. | 17 Aug 2021 | 288 | 0 | - | 52.1 | 15,002 | Common Stock |
| Kymera Therapeutics Inc | Richard Chesworth | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Richard Chesworth | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2020 | 351,119 | 351,119 | - | - | Stock Option (Right to Buy) |